Skip to main content

Table 2 Eighteen subsequent malignancies occurred in PPBL patients

From: Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification

Patients Delay between PPBL and subsequent malignancy’s diagnosis Type of malignancy Follow-up
UPN36 38 months DLBCL 56 months
UPN47 20 months SMZL +65 months
UPN57 92 months DLBCL 99 months
UPN63 Diagnosis of PPBL and lymphoma was concomitant DLBCL +13 months
UPN71 77 months SMZL +86 months
UPN83 120 months DLBCL +131 months
UPN1 264 months MGUS +348 months
UPN10 144 months MGUS +148 months
UPN157 44 months MGUS +47 months
UPN118 Diagnosis of PPBL and MGUS was concomitant MGUS +36 months
UPN163 Diagnosis of PPBL and MGUS was concomitant MGUS +57 months
UPN105 Diagnosis of PPBL and MGUS was concomitant MGUS +42 months
UPN5 96 months Mammary carcinoma +272 months
UPN6 3 months Pulmonary carcinoma 3 months
UPN70 22 months Pulmonary carcinoma +22 months
UPN86 132 months Pulmonary carcinoma +146 months
UPN160 114 months Pulmonary carcinoma 112 months
UPN67 156 months Cervical carcinoma +181 months
  1. Six patients developed solid tumors (4 pulmonary cancers, 1 breast cancer and 1 cervical carcinoma) and 6 patients hematological malignancies (diffuse large B-cell lymphoma (DLBCL) in 4 cases, splenic marginal zone lymphoma (SMZL) in 2 cases) and 6 patients monoclonal gammopathies of undetermined significance (MGUS) (IgM)